Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: An update

Journal of Human Hypertension

Volumn 21, Issue 9, 2007, Pages 699-708

  Chrysant, S G ^a   Dimas, B ^b   Shiraz, M ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b SOUTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; CAPTOPRIL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; EPROSARTAN; FELODIPINE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; OLMESARTAN; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; BINDING AFFINITY; BRONCHITIS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIZZINESS; DRESSLER SYNDROME; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; FLU LIKE SYNDROME; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MEDLINE; MONOTHERAPY; NONHUMAN; RECURRENT DISEASE; REVIEW; STRUCTURE ACTIVITY RELATION; TREATMENT INDICATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CLINICAL TRIALS; DIURETICS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; IMIDAZOLES; TETRAZOLES;

EID: 34548323875     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002241     Document Type: Review

References (70)

1. Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 2001; 87(8A): 37C-43C.
2. Chrysant SG, Chrysant GS. Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Expert Opin Pharmacother 2004; 5:657-667.
3. Puchler K, Laeis P, Stumpe KC. Blood pressure response, but not adverse event incidence correlates with dose of angiotensin II antagonist. J Hypertens 2001; 19(Suppl 1): S41-S48.
4. Neutel JM, Elliott WJ, Izzo JL, Chen CL, Masonson HN. Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, assessed by ambulatory blood pressure measurements. J Clin Hypertens 2002; 4: 325-331.
5. Brunner HR, Nussberger J. Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1 receptor antagonist. J Hypertens 2001; 19(Suppl 1): S15-S20.
6. Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin H antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J Hypertens 2001; 19 Suppl 1): S49-S56.
7. Stumpe KO, Ludwig M. Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J Hum Hypertens 2002; 16 Suppl 2): S24-S28.
8. Chrysant SG, Marbury TC, Robinson TD. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens 2003; 17: 425-432.
9. Chrysant SG, Weber MA, Wang AC, Hinman DJ. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004; 17: 252-259.
10. Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3: 283-291.
11. Smith DH, Dubiel R, Jones M. Use 24-h ambulatory blood pressure monitoring to assess antihypertensive efficacy: A comparison of olmesartan medoxomil, losartan, potassium, valsartan and irbesartan. Am J Cardiovasc Drugs 2005; 5: 41-50.
12. Stumpe KO. Olmesartan compared with other angiotensin II receptor antagonists: Head-to-head trials. Clin Ther 2004; 26(Suppl A): A33-37.
13. Brunner HR, Stumpe KO, Januszewicz A. Antibypertensive efficacy of olmesartan medoxomil and cande-sartan cilexetil assessed by 24-h ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest 2003; 23: 419-430.
14. Giles TD, Oparil S, Silfani TN, Wang A, Walker JF. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens 2007; 9: 187-195.
15. Koike H, Sada T, Mizuno M. In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist. J Hypertens 2001; 19(Suppl 1): S3-S14.
16. Schwocho LR, Masonson HN. Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol 2001; 41: 515-527.
17. Warner GT, Jarvis B. Olmesartan medoxomil. Drugs 2002; 62: 1345-1353.
18. Mire DE, Silfani TN, Pugsley MK. A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker. J Cardiovasc Pharmacol 2005; 46: 585-593.
19. Von Bergman K, Laeis P, Püchler K, Sudhop T, Schwocho LR, Gonzales L. Olmesartan medoxomil: Influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. J Hypertens 2001; 19(Suppl 1): S38-S40.
20. Laeis P, Püchler K, Kirch W. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens 2001; 19(Suppl 1): S21-S32.
21. Mizuno M, Sada T, Ikeda W, Fukuda N, Myamoto M, Yanagisawa H et al. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol 1995; 285: 181-188.
22. Koike H. New pharmacologic aspects of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 2001; 87: 33-36.
23. Miyazaki M, Takai S. Antiatherosclerotic efficacy of olmesartan. J Hum Hypertens 2002; 16(Suppl 2): S7-S12.
24. Takai S, Jin D, Sakaguchi M, Miyazaki M. Chymase-dependent angiotensin II formation in human vascular tissue. Circulation 1999; 100 654-658.
25. Ihara M, Urata H, Kinsoshita A, Suzumiya J, Sasaguri M, Kikuchi M et al. Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension 1999; 33: 1399-1405.
26. Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: Evidence from comparative pharmacological interruption of the renin system. Hypertension 1998; 32: 387-392.
27. Chrysant SG. Vascular remodeling: The role of angiotensin converting enzyme inhibitors. Am Heart J 1998; 135: S21-S30.
28. Chrysant SG, Marbury TC, Silfani TN. Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: A comparison of olmesartan medoxomil and amlodipine besylate. Blood Press Monit 2006; 11: 135-141.
29. Sellin L, Stegbauer J, Laeis P, Rump LC. Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension. J Hypertens 2005; 23 2083-2092.
30. Fogari R, Zoppi A, Mugellini A, Preti P, Destro M, Rinaldi A et al. Hydrocholorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy. Adv Ther 2006; 23: 680-695.
31. Chrysant SG, Dubiel R, Walker F, Izzo J. Efficacy of olmesartan medoxomil (OM) and hydrochlorothiazide (HCTZ) in achieving blood pressure goals in patients with stage 2 systolic hypertension: Effect of Body Mass Index (BMI). J Clin Hypertens (Abstr) 2006; 8: A136.
32. Chrysant SG, Dubiel R, Walker F, Izzo J. Efficacy of olmesartan medoxomil (OM) and OM/Hydrochloro-thiazide (HCTZ) in achieving blood pressure goals in hypertensive patients with stage 2 systolic hypertension: Effects in non-black patients. J Clin Hypertens (Abstr 2006; 8: A136.
33. Izzo JL, Neutel JM, Silfani T, Dubiel R, Walker F. Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/ HCTZ: Results of an open-label titration study. J Clin Hypertens 2007; 9: 36-44.
34. Izzo JL, Neutel JM, Silfani T, Walker F. Titration of HCTZ to 50mg daily in individuals with stage 2 systolic hypertension pretreated with an angiotensin receptor blocker. J Clin Hypertens 2007; 9: 45-48.
35. Chabanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. The JNC-7 report. JAMA 2003; 289: 2560-2571.
36. American Diabetes Association. Hypertension management in adults with diabetes. Diabetes Care 2004; 27(Suppl. 1): S65-S67.
37. Chrysant SG, Chrysant GS. The pleiotropic effects of angiotensin receptor blockers. J Clin Hypertens 2006; 8: 261-268.
38. Malmqvist K, Ohman KP, Lind L, Nystrom F, Kahan T. Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: The Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SYLVHIA). J Cardiovasc Pharmacol 2003; 42: 719-726.
39. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, deFaire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint (LIFE) reduction hypertension study: A randomized trial against atenolol. Lancet 2002; 359: 995-1003.
40. Pitt B, Pool-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ et al. Effect of losartan compared with captopril on mortality in patients with Tymptomatic heart failure: A randomized trial: the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-1587.
41. Dicstein K, Kjekshus J, the OPTIMAAL Steering Committee for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high risk patients after acute myocardial infarction: The OPTIMAAL randomized trial. Lancet 2002; 360: 752-760.
42. Cohn JN, Tognoni G. Valsartan Heart Failure Trial investigators. A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675.
43. Pfeffer MA, McMurray JT, Velasquez EJ, Rouleau JL, Kober L, Maggioni AP, et al., for the Valsartan Acute Myocardial Infarction Trial (VALIANT) investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction or both. N Engl J Med 2003; 349: 1893-1906.
44. Pfeffer MA, Swedberg K, Granger CD, Held P, McMurray JJ, Michelson EL et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-overall programme. Lancet 2003; 362: 759-766.
45. Viberti G, Wheeldon NM, for the Micro-Albuminuria Reduction with VALsartan (MARVAL) Study Investigators. Micro-albuminuria reduction with valsartan in patients with type-2 diabetes mellitus. A blood pressure-independent effect. Circulation 2002; 106: 672-678.
46. Parving HH, Lehert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type-2 diabetes. N Engl J Med 2001; 385: 870-878.
47. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type-2 diabetes. N Engl J Med 2001; 345: 851-860.
48. Brenner BM,.Cooper ME, Dezeeuw D, Keane WF, Mitch WE, Parving HH et al. Effects of losartan on renal and cardiovascular outcomes in patients with type-2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
49. Chrysant SG. Stroke prevention with losartan in the context of other antihypertensive drags. Drugs Today 2004; 40: 791-801.
50. Chrysant SG. Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin converting enzyme inhibitors. J Hum Hypertens 2005; 19: 923-931.
51. Kjeldsen SE, Dahlof B, Devereux RB, Julius S, Aurup P, Edelman J et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: A Losartan Intervention For Endpoint (LIFE) sub-study. JAMA 2002; 288: 1491-1498.
52. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-886.
53. Papademetriou V, Farsang C, Elmfeldt D, Hofman A, Lithell H, Olofsson B et al. Stroke prevention with the angiotensin II type 1 receptor blocker candesartan in elderly patients with isolated systolic hypertension: The Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol 2004; 44: 1175-1180.
54. Schrader J, Luders S, Kulschewski A, Hammersen F, Zuchner C, Venneklaas U et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: Principal results of a prospective randomized control study (MOSES). Stroke 2005; 36 1218-1226.
55. Mochizuki S, Dahlof B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I et al. Valsartan in Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): A randomized, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 360 1431-1439.
56. Julius S, Kjeldsen SE, Weber MA, Brunner HR, Ekman S, Hansson L et al. Outcomes in hypertensive patients at high risk treated with regimens based on valsartan or amlodipine: The VALUE randomized trial. Lancet 2004; 363: 2022-2031.
57. Morawietz H, Ruecksloss U, Niemann B, Duerschmidt N, Galle J, Hakim K et al. Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation 1999; 100: 899-902.
58. Miyazaki M, Takai S. Antiatherosclerotic efficacy of olmesartan. J Hum Hypertens 2002; 16(Suppl. 2): S7-S12.
59. Inukai T, Yoshida N, Wakabayashi S, Inukai Y, Matsutomo R, Takanashi K et al. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers effectively and directly potentiate superoxide scavenging by polymorphonuclear-leukocytes from patients with type 2 diabetes mellitus. Am J Med Sci 2005; 329: 222-227.
60. Kurtz TW, Pravenec M. Antidiabetic mechanisms and angiotensin II receptor antagonists: Beyond the renin-angiotensin system. J Hypertens 2004; 22: 2253-2261.
61. Guerra-Cuesta JL, Manton M, Rodriguez-Feo JA, Jimenez AM, Gonzalez-Fernandez F, Rico LA et al. Effect of losartan on human platelet activation. J Hypertens 1999; 17: 447-452.
62. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-analysis. J Am Coll Cardiol 2005; 45: 1832-1839.
63. Wachtel K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B et al. Angiotensin II receptor blockade reduces new onset atrial fibrillation and subsequent stroke compared to atenolol. J Am Coll Cardiol 2005; 45: 712-719.
64. Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence within newly diagnosed hypertensive patients. J Hum Hypertens 2002; 16; 569-575.
65. Marentette MA, Gerth WC, Billings DK, Zarnke KB. Antihypertensive persistence and drug class. Can J Cardiol 2002; 18: 649-656.
66. Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 2002; 89: 18A-25A.
67. Diener HC. Prevention Regimen For Effectively avoiding Second Strokes (PRoFESS): Rationale and design. Cerebrovasc Dis 2000; 10: 147-150.
68. Haller H, Viberti GC, Mimran A, Remuzzi G, Rabelink AJ, Ritz E et al. Preventing micro-albuminuria in patients with diabetes: Rationale and design of the Randomized Olmesartan and Diabetes Micro-albuminuria Prevention (ROADMAP) study. J Hypertens 2006; 24: 403-408.
69. Fliser D, Wagner KK, Loos A, Tsikas D, Haller H. Chronic angiotensin II receptor blockade reduces intrarenal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 2005; 16: 1135-1140.
70. Mizuno M, Sada T, Kato M, Koike H. Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes. Hypertens Res 2002; 25: 271-278.